UNSPSC 51282925: Irloxacin

This classification denotes a quinolone antibiotic with the molecular formula C16H13FN2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 36SG77D21B, chemically known as 1,4-dihydro-1-ethyl-6-fluoro-4-oxo-7-(1h-pyrrol-1-yl)-3-quinolinecarboxylic acid but generally known as irloxacin, which bears US NIH Compound Identifier 65828. European Medicines Agency schedules Irloxacin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08296MIG.

UNSPSC 51282925 Irloxacin (Commodity) does not align with the recent state and local contract opportunities tagged to this code. The solicitations posted under 51282925 involve naloxone and drug deactivation systems, therapeutic pharmacy initiatives for direct-to-manufacturer prescriptions, medical and first aid supplies for fire rescue operations, and generic multi-source pharmaceuticals and OTC products — none of which are irloxacin-specific pharmaceuticals. The code shows a fundamental mismatch between its nominal scope and what state and local governments are actually procuring under it.

Recent opportunities attributed to this code span health agencies, state procurement alliances, and municipal fire departments across Florida, Texas, and Minnesota, but the products being solicited (naloxone kits, first aid supplies, generic pharmaceuticals through wholesaler networks, and direct pharmacy benefit management initiatives) fall outside the antibiotic/antimicrobial drug category that irloxacin represents. The largest visible opportunity is the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) RFP for generic multi-source pharmaceuticals and OTC products due March 26, 2026, which draws participation from state and local facilities across Minnesota and Oregon. Other recent activity includes Seminole County, Florida's IFB for naloxone and drug deactivation systems (due July 26, 2023) and the City of Tampa's IFB for medical and first aid supplies for the Fire Department Rescue Division (estimated contract value $700,000, due March 13, 2026). Pursuit of this code is not recommended without confirmation from the issuing jurisdiction that irloxacin or closely related fluoroquinolone antibiotics are actually part of their pharmaceutical procurement scope, as the current tagging appears to reflect a cataloging error rather than active demand for this specific drug class.